Welcome to our dedicated page for Invivyd news (Ticker: IVVD), a resource for investors and traders seeking the latest updates and insights on Invivyd stock.
Invivyd, Inc. develops monoclonal antibody therapies for serious viral infectious diseases, with an initial focus on SARS-CoV-2. Company news commonly covers PEMGARDA (pemivibart), which received U.S. FDA emergency use authorization for pre-exposure prevention of COVID-19 in certain immunocompromised individuals, and pipeline work involving VYD2311 for COVID-19, VBY329 for RSV, and VMS063 for measles.
Updates also address clinical-study design and tolerability research, antibody platform presentations, financial results and corporate updates, public education efforts around antibodies and immune health, and Nasdaq inducement equity grants under the company’s 2026 Inducement Plan.
Invivyd, Inc. (Nasdaq: IVVD) has announced a significant improvement in its projected 2024 year-end cash position by $20-25 million, expecting to end the year with at least $75 million in cash and cash equivalents. The company achieved these improvements through resource realignment to focus on the commercial launch of PEMGARDA™ and the discovery of novel monoclonal antibodies. Despite eliminating fourteen full-time positions, Invivyd remains positive about its 2024 revenue projections.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.